Drugs / Intravenous immunoglobulin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07806916 Comparator | Sep 2026 → Jun 2027 expected | Guillain-Barre syndrome | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Intravenous immunoglobulin | “The same brand of intravenous immunoglobulin (IVIG) was administered across different study sites” NCT07806916 ↗ |
| Known as | IVIG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07806916 ↗ |
| Modality | Protein / enzyme biologic | “intravenous immunoglobulin (IVIG)” NCT07806916 ↗ |
| Route | Intravenous | “Intravenous immunoglobulin (IVIG)” NCT07806916 ↗ |